CoChat

Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci6863

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 6

  1. Hawkins, 1996, Cancer Res, 56, 892
  2. O’Connor, 1997, Cancer Res, 57, 4285
  3. Waldman, 1995, Cancer Res, 55, 5187
  4. Geoffroy, 1994, Oncol Res, 6, 581
  5. Wyllie, 1997, Eur J Cell Biol, 73, 189
  6. Cory, 1979, Cancer Res, 39, 4905

Cited by

See all 1,044

Metadata

Authors
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
Affiliations
  • Howard Hughes Medical Institute (US)
  • Georgetown University (US)
  • Johns Hopkins University (US)
Corresponding author
Vogelstein, Bert
Venue
Journal of Clinical Investigation
Published
1999-08-01
Volume
104
Issue
3
Pages
263-269
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1982097971
Cited by
1,044
References
33
Citations by year
2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
FWCI
22.48
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Foundation for Cancer Research
  • Johns Hopkins University
  • National Institutes of Health
  • National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
MeSH terms
Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.